|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II.
|
12663475 |
2003 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although the renin-angiotensin system has been implicated in the pathogenesis of diabetic nephropathy, angiotensin I-converting enzyme inhibitors have a beneficial effect on diabetic nephropathy independently of their effects on blood pressure and plasma angiotensin II levels.
|
22318421 |
2012 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This risk could be attributed to the increasing activity of ACE and angiotensin II level in the presence of D allele and decreasing NO production in the presence of T allele accelerating diabetic nephropathy.
|
22026967 |
2012 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that the augmented angiotensinogen mRNA levels in segment 3 and angiotensinogen protein levels in segments 1 and 3 may contribute to the progression of diabetic nephropathy.
|
24910532 |
2014 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Microvascular complications were graded as follows: neuropathy by clinical assessment, electrophysiology, vibration and cooling detection thresholds, heart rate variability, and corneal confocal microscopy; retinopathy by ultra-wide-field retinal imaging; and DKD by renal hemodynamic function measured by inulin and para-aminohippurate clearance at baseline and after intravenous infusion of angiotensin II.
|
30275283 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Podocytes have also been shown to express angiotensin-converting enzyme 2 (ACE2), which can decrease angiotensin II levels by generation of angiotensin-(1-7).Nadarajah et al. now show that increased podocyte ACE2 activity can attenuate the development of diabetic nephropathy.
|
22791320 |
2012 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High glucose and angiotensin-II (Ang-II) levels are the known important mediators of diabetic nephropathy.
|
16728425 |
2006 |
|
Diabetic Nephropathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Angiotensin II type 1 receptor antagonists (AIIA) are beneficial for the prevention of atherosclerosis and diabetic nephropathy suggesting that angiotensin II (Ang II) promotes the development of these diseases.
|
17487826 |
2007 |
|
Diabetic Nephropathy
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Our study suggested that the AGT gene plays an important role in diabetic nephropathy.
|
12728975 |
2003 |
|
Diabetic Nephropathy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Ameliorative potential of angiotensin1-7/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats.
|
20383342 |
2010 |
|
Diabetic Nephropathy
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats.
|
17890855 |
2008 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effects of some RAAS gene variants, including angiotensin converting enzyme (ACE), angiotensinogen (AGT) and angiotensin II type 1 receptor (AT1R), on the risk for DN have been studied more extensively, but there has been controversy.
|
26619914 |
2016 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
ET-1 and AngII were also significantly decreased in three treatment groups (p < 0.01 vs. the DKD group), especially in the P + A group.
|
29185789 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The widely studied candidate genes of the renin-angiotensin-aldosterone system, angiotensinogen (AGT), and angiotensin II receptor type 1 (AGTR1), are implicated in the development of diabetic nephropathy (DN).
|
21607620 |
2012 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data indicate that increasing AcSDKP by blocking the ACE N-domain facilitates sodium excretion and ameliorates diabetic kidney disease independent of intrarenal angiotensin II regulation.
|
30185469 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, normalizing testosterone and inhibiting renal angiotensin II have a renoprotective effect against DN in HG male rats.
|
30970225 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with people without DKD, those with DKD had higher urine AOG (170 vs. 15 μg/g) and CTSD (147 vs. 31 μg/g).
|
28468961 |
2017 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, the changes of VEGF expression was examined in the experimental diabetic nephropathy to determine whether these changes were modified by renoprotective intervention by blockers of angiotensin II receptors.
|
15031673 |
2004 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The anti-DN benefit of vitamin D can be enhanced when administrated in combination with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
|
30287151 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the diabetic milieu per se , hemodynamic changes, oxidative stress and local growth factors such as angiotensin II (AII) are considered to be mediators in the pathogenesis of diabetic nephropathy, the underlying pathways mediating the changes in glomerular endothelial cells (GECs) are not well understood.
|
27358275 |
2017 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although key signal transduction and gene regulation mechanisms have been identified, especially those related to the effects of hyperglycaemia, transforming growth factor β1 and angiotensin II, progress in functional genomics, high-throughput sequencing technology, epigenetics and systems biology approaches have greatly expanded our knowledge and uncovered new molecular mechanisms and factors involved in DN.
|
25003613 |
2014 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme (ACE) generates angiotensin II from angiotensin I, which plays a critical role in the pathophysiology of diabetic nephropathy.
|
19034303 |
2008 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
A key driving factor of diabetic nephropathy is angiotensin II acting via the G-protein-coupled cell membrane type 1 receptor.
|
30190172 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme 2 (ACE2) is highly expressed in the kidney and recognized to be renoprotective by degrading Angiotensin II to Angiotensin (1-7) in diabetic nephropathy.
|
25791940 |
2015 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In fact, it has been shown that angiotensin II is involved in almost every pathophysiological process implicated in the development of diabetic nephropathy (haemodynamic changes, hypertrophy, extracellular matrix accumulation, growth factor/cytokine induction, ROS formation, podocyte damage, proteinuria, interstitial inflammation).
|
15606719 |
2004 |